New study below [1].
I posted a series on inflammation 3 years ago [2] [3] [4] [5].
Basically, chronic subclinical inflammation is a killer. It predicts the prognosis for any type of treatment (or no treatment at all). I can't cure my cancer but I can control inflammation. The key is nuclear factor-kappaB [NF-kB] wich is chronically activated in cancers. Polyphenols are all inhibitors of NF-kB.
The new study looked at: "plasma systemic immune-inflammation index (SII), albumin, and fibrinogen levels in metastatic castration-resistant prostate cancer (mCRPC) patients treated with first-line docetaxel"
I don't know anything about the "plasma systemic immune-inflammation index", but albumin & fibrinogen were discussed in [3] & [4], respectively. But note that: "SII level was associated with neutrophil-to-lymphocyte ratio (NLR)", which I covered in [2].
"Of the three target parameters, we found that patients with none abnormalities of the three parameters showed the best prognosis, and patients with at least any two abnormalities of them showed markedly worse prognosis than patients with any one abnormalities of the three parameters"
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/314...
Int Urol Nephrol. 2019 Aug 27. doi: 10.1007/s11255-019-02265-4. [Epub ahead of print]
Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel.
Man YN1, Chen YF2.
Author information
1
Department of Radiation Oncology, The Second Hospital of Tianjin Medical University, Ping-Jiang Road, He-Xi District, Tianjin, 300060, China. nannan871220@126.com.
2
Department of Radiation Oncology, The Second Hospital of Tianjin Medical University, Ping-Jiang Road, He-Xi District, Tianjin, 300060, China.
Abstract
PURPOSE:
To evaluate the prognostic value of pretreatment plasma systemic immune-inflammation index (SII), albumin, and fibrinogen levels in metastatic castration-resistant prostate cancer (mCRPC) patients treated with first-line docetaxel and to screen out the patients with the greatest risk for poor prognosis.
METHODS:
The plasma SII, albumin, and fibrinogen levels were examined before treatment and analyzed with patient clinicopathological parameters and overall survival (OS). The survival analysis was performed using the Kaplan-Meier method, and prognostic factors were assessed using the Cox proportional hazard regression model.
RESULTS:
The incidences of elevated SII level, hypoproteinemia, and hyperfibrinogenemia were 52.51%, 25.14%, and 27.93%, respectively. SII level was associated with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) (P < 0.001). Albumin level was found closely correlated with ECOG PS (P = 0.006), PLR (P = 0.042), and hemoglobin (P = 0.009), but not other parameters. Elevated plasma fibrinogen level was significantly associated with Eastern Cooperative Oncology Group performance status (ECOG PS) (P = 0.009), visceral metastases (P < 0.001), and PLR (P = 0.001). In multivariate Cox regression model, visceral metastases SII (HR 2.133, 95% CI 1.163-3.913; P = 0.014), albumin (HR 0.540, 95% CI 0.307-0.949; P = 0.032), and fibrinogen (HR 1.888, 95% CI 1.069-3.335; P = 0.029) were further confirmed to be the independent prognostic factors for OS. Of the three target parameters, we found that patients with none abnormalities of the three parameters showed the best prognosis, and patients with at least any two abnormalities of them showed markedly worse prognosis than patients with any one abnormalities of the three parameters (P < 0.001).
CONCLUSIONS:
Pretreatment SII, albumin, and fibrinogen are independent prognostic factors in mCRPC patients treated with first-line docetaxel. Moreover, the combined use of SII, albumin, and fibrinogen levels may help us to identify the high-risk populations for treatment decisions.
KEYWORDS:
CRPC; D-dimer; Fibrinogen; Prognosis; SII
PMID: 31456101 DOI: 10.1007/s11255-019-02265-4
***
[2] healthunlocked.com/advanced...
[3] healthunlocked.com/advanced...
